Top Banner
Red Blood Cells Substitutes – Future Vision – António Filipe Sousa Nº64427 MBioNano
12

Red Blood Cells Substitutes – Future Vision –

Nov 21, 2014

Download

Technology

António Sousa

The purpose of this paper is to determine a valid application of vesicles for encapsulating a concentrated human Hb, and diferent kinds of enzymes, in order to obtain a fully operational and self functional artificial red blood cell. The resulting Hb-vesicle (HbV) can serve as an O2 carrier with the ability comparable to red blood cells (RBC).
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Red Blood Cells Substitutes  – Future Vision –

Red Blood Cells Substitutes – Future Vision –

António Filipe SousaNº64427 MBioNano

Page 2: Red Blood Cells Substitutes  – Future Vision –

Introduction • Advantages and Problems• Liposome-encapsulated hemoglobin (LH)

Preparation Method • Products for use

Parameteres for using HbV• Particles Size• Oxygen-Carrying Capacity • Physiological Capacity of the Reticuloendothelial System

for the Degradation of Hemoglobin Vesicles

Conclusions • Is it possible?• Future Investigations

Page 3: Red Blood Cells Substitutes  – Future Vision –

The purpose of this paper is to determine a valid application of vesicles for encapsulating a concentrated human Hb, and diferent kinds of enzymes, in order to obtain a fully operational and self functional artificial red bloood cell. The resulting Hb-vesicle (HbV) can serve as an O2 carrier with the ability comparable to red blood cells (RBC).

Some advantages of obtaining Hb-based O2 carrieres (HBOCs) are:• Absence of blood-type antigens and transmission of known and unknown blood-borne disease;• Long Term stability and storage;• Low toxicity and prompt metabolism, even after massive infusion;

• Physichochemical properties that are adjustable to resemble those of human blood and

• Reasonable production expense and cost performance. [1]

Introduction

[2]

Page 4: Red Blood Cells Substitutes  – Future Vision –

Liposome-encapsulated hemoglobin (LH) was chosen for this paper as a promising artificial oxygen (O2) carrier. The capsular structure of LH is favorable for preserving the chemical environment for Hb and reducing its side effects. [3]

Introduction

The main purpose is to mimic the double layer membrane of the biological red blood cells. So, we want to fabricate a artificial membrane with optimal Amounts of Protein (49%), Lipid(43%) and Carbohydrate (8%)

[1]

Page 5: Red Blood Cells Substitutes  – Future Vision –

Preparation Method The method chosen for the preparation of the artificial red

blood cellssuspension would be the follow at sterile conditions:

• Human Hb purified from outdated, donated blood. Preparation of polyHb based on crosslinking polyHb with superoxyde dismutase and catalase.• At the same time, metHb reductase, and other different kinds of enzymes can be included with the PolyHb.

• Preparation of polyHb with pyridoxal 5’-phosphate as an allosteric effector (increases oxygen affinity).

• The lipid bilayer was composed of a mixture of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), cholesterol, and 1,5-O-dihexadecyl-N-succynyl-L-glutamate (DHSG) and 1,2- distearoyl-sn-glycero-3-phosphatidylethanolamine-N-PEG5000. [4]

• HbVs were suspended in a physiological salt solution, sterilized using filters (pore size, 0.45 um). [4]

• Parameters of the HbV are as follows: particle diameter, 250 nm and oxygen affinity (P50), 30 Torr. [4]

Page 6: Red Blood Cells Substitutes  – Future Vision –

Preparation Method Molecule Transportation:

Sodium-potassium pump,Calcium pump,Amino acids,Glucose. 2 Molecules of lactate and 2 of

ATP, by the Embden-Meyerhof way.

Enzymes required:Hexokinase,Phosphofructokinase,Piruvate Kinase,NAD coenzyme.Anti-Oxydant protection:

Superoxyde dismutase,Superoxyde catalase,NADPH coenzyme,Others like, metahemoglobin reductase, G6P, GSH and Vitamin E.

Page 7: Red Blood Cells Substitutes  – Future Vision –

Parameteres for using HbV

• Particles Size

Is a very important parameter to consider using HbV as an oxygen carrier. Since the estimated diameter of the smallest blood capillaries in the human body is 4–7 um, the particle sizes should optimally be below 4 um to avoid embolism.

(a) The transmittance electron micrograph of rat blood 1 day after infusion of HbV. Many HbV particles are visible in the red circles. (b) Flow patterns of the mixture of HbV and RBC suspended in recombinant human serum albumin in a narrow tube (centerline flow velocity: 1 mm/s. The RBCs tend to flow in the centerline, whereas HbV particles are dispersed homogeneously in a suspension medium.

[1]

Page 8: Red Blood Cells Substitutes  – Future Vision –

Parameteres for using HbV

• Oxygen_carrying Capacity

With this paper we want to mimic the RBC O2 affinity, so we expect to obtain a curve of this kind:

HbV should act as a particle in the blood and not as a solute; the colloid osmotic pressure of the HbV suspension should be nearly zero. The rheological property of an artificial oxygen carrier is important because the infusion amount should be considerably large, which might affect the blood viscosity and hemodynamics. The measurement of the O2-release rate of the HbV must be similar to the RBCs.

Page 9: Red Blood Cells Substitutes  – Future Vision –

Parameteres for using HbV

• Physiological Capacity of the Reticuloendothelial System for the Degradation of Hemoglobin Vesicles

HbV particles are recognized as foreign materials and finally captured mainly by the reticuloendothelial system. These are outstanding characteristics in comparison with molecular Hb that shows a shorter circulation time because it is filtered through the kidneysIn a series of safety studies of HbV, it has been clarified that the cellular structure and the size of the HbV are advantageous for maintaining a steady blood circulation without vasoconstriction and hypertension.

34 male Wistar rats

N=12 with HbV infusions (10ml/Kg, 1ml/min)

N=10 Control Group

N=12 with Salt infusions (10ml/kg, 1ml/min)

Next we will see the efects of HbV in the RES of rats, during a study by, Hiromi et al.

Note: DRI=Daily Repeated Infusion

[5]

Page 10: Red Blood Cells Substitutes  – Future Vision –

Parameteres for using HbV The results

were:

[5]

Numbers of RBC’s showed moderate changes.Dilution of Blood, and hypervolemia.Slight hypertension in the first day after DRI.

Page 11: Red Blood Cells Substitutes  – Future Vision –

Conclusions

Advantages of artificial O2 carriers including HbV are the absence of blood-type antigens and infectious viruses, along with stability for a long-term storage for any emergency that might overwhelm the RBC transfusion capacity.The possibility of obtaining a fully independent HbV, with not only hemoglobin, but also with all the enzymes necessary for a regular oxygen flow betwen blood and tissues, is becoming a possibility and a area of investigation with much interest.

…Super athelitcs!!

…No more blood respiratory deseases!!

…Only 5-6 inspirations per minute!!

The future?

Page 12: Red Blood Cells Substitutes  – Future Vision –

Bibliography

[1] H. Sakai, et al, (2007). Hemoglobin-vesicles as artificial oxygen carriers: present situation and future visions. Journal of Internal Medicine, 263; 4–15.

[2] Chang, Thomas Ming Swi(2006)'Evolution of Artificial Cells Using Nanobiotechnology of Hemoglobin Based RBC Blood Substitute as an Example',Artificial Cells, Blood Substitutes, and Biotechnology,34:6,551 — 566

[3] Matsumoto T, et al. Model analysis of local oxygen delivery with liposome-encapsulated hemoglobin. Med Eng Phys (2008), doi:10.1016/j.medengphy.2008.08.005

[4] Hiromi Sakai, et al (2004). Metabolism of hemoglobin-vesicles (artificial oxygen carriers) and their influence on organ functions in a rat model. Biomaterials 25, 4317–4325.

[5] Hiromi Sakai, et al (2004). Physiological Capacity of the Reticuloendothelial System for the Degradation of Hemoglobin Vesicles (Artificial Oxygen Carriers) after Massive Intravenous Doses by Daily Repeated Infusions for 14 Days. The Journal of Pharmacology and Experimental Therapeutics, 311:874–884.

[6] Jian Zhao, et al (2006). Preparation of hemoglobin-loaded nano-sized particles with porous structure as oxygen carriers. Biomaterials 28, 1414–1422.

[7] Robert M. Winslow (1999). New Transfusion Strategies: Red Cell Substitutes. Annu. Rev. Med. 50:337.53